Director Kim R. Tsuchimoto of Monopar Therapeutics filed a Form 4 on August 27, 2026, reporting six open-market sales of common stock executed on August 26, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Kim R. Tsuchimoto, listed as a Director of Monopar Therapeutics (NASDAQ:MNPR).
  • Total shares sold: 4,090 shares of common stock disposed of across six transactions, all on August 26, 2026.
  • Price range: Weighted average sale prices ranged from $108.83 to $113.84 per share across the six tranches, with individual transaction prices spanning $108.07 to $114.34.
  • Remaining ownership: Following all reported transactions, the reporting person directly beneficially owned 7,396 shares of common stock.
  • Rule 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 27, 2026.
  • Full price detail available: The reporting person undertook to provide full information on shares sold at each separate price within each range, upon request to Monopar Therapeutics, any security holder, or SEC staff.

Tsuchimoto's Six-Tranche Sale Under 10b5-1 Plan

According to the filing, Director Kim R. Tsuchimoto sold a total of 4,090 shares of Monopar Therapeutics common stock on August 26, 2026, across six separate tranches. The transactions were conducted under a Rule 10b5-1 plan that the reporting person executed on May 27, 2026. All sales are reported as direct ownership disposals, using transaction code "S."

The six tranches, as disclosed, were: 485 shares at a weighted average price of $108.83 (range $108.07 to $109.05); 615 shares at $109.56 (range $109.07 to $110.04); 700 shares at $110.65 (range $110.14 to $111.05); 1,098 shares at $111.84 (range $111.30 to $112.27); 602 shares at $112.93 (range $112.30 to $113.25); and 590 shares at $113.84 (range $113.35 to $114.34). Because each price column reflects a weighted average, the filing notes that additional detail on shares sold at each individual price is available upon request.

Prior to the first reported transaction, the filing indicates Tsuchimoto held 11,486 shares. After all six sales, direct beneficial ownership stood at 7,396 shares, according to the filing. No derivative securities transactions were reported in Table II. The Form 4 was signed by Quan Vu as attorney-in-fact on August 27, 2026.

What Was Disclosed

The filing discloses six sales of Monopar Therapeutics common stock by Director Kim R. Tsuchimoto on August 26, 2026, totaling 4,090 shares sold at weighted average prices between $108.83 and $113.84 per share, carried out under a pre-established Rule 10b5-1 plan dated May 27, 2026.